234 related articles for article (PubMed ID: 30366412)
1. Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia.
Stuani L; Riols F; Millard P; Sabatier M; Batut A; Saland E; Viars F; Tonini L; Zaghdoudi S; Linares LK; Portais JC; Sarry JE; Bertrand-Michel J
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30366412
[No Abstract] [Full Text] [Related]
2. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.
Boutzen H; Saland E; Larrue C; de Toni F; Gales L; Castelli FA; Cathebas M; Zaghdoudi S; Stuani L; Kaoma T; Riscal R; Yang G; Hirsch P; David M; De Mas-Mansat V; Delabesse E; Vallar L; Delhommeau F; Jouanin I; Ouerfelli O; Le Cam L; Linares LK; Junot C; Portais JC; Vergez F; Récher C; Sarry JE
J Exp Med; 2016 Apr; 213(4):483-97. PubMed ID: 26951332
[TBL] [Abstract][Full Text] [Related]
3. The role of IDH mutations in acute myeloid leukemia.
Montalban-Bravo G; DiNardo CD
Future Oncol; 2018 Apr; 14(10):979-993. PubMed ID: 29543066
[TBL] [Abstract][Full Text] [Related]
4. Metabolic syndromes and malignant transformation: where the twain shall meet.
Bhagwat N; Levine RL
Sci Transl Med; 2010 Oct; 2(54):54ps50. PubMed ID: 20962328
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.
Balss J; Thiede C; Bochtler T; Okun JG; Saadati M; Benner A; Pusch S; Ehninger G; Schaich M; Ho AD; von Deimling A; Krämer A; Heilig CE
Leukemia; 2016 Apr; 30(4):782-8. PubMed ID: 26582645
[TBL] [Abstract][Full Text] [Related]
6. Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability.
Thomas D; Wu M; Nakauchi Y; Zheng M; Thompson-Peach CAL; Lim K; Landberg N; Köhnke T; Robinson N; Kaur S; Kutyna M; Stafford M; Hiwase D; Reinisch A; Peltz G; Majeti R
Cancer Discov; 2023 Feb; 13(2):496-515. PubMed ID: 36355448
[TBL] [Abstract][Full Text] [Related]
7. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia.
Reitman ZJ; Duncan CG; Poteet E; Winters A; Yan LJ; Gooden DM; Spasojevic I; Boros LG; Yang SH; Yan H
J Biol Chem; 2014 Aug; 289(34):23318-28. PubMed ID: 24986863
[TBL] [Abstract][Full Text] [Related]
8. Detection of IDH1 R132H mutation in acute myeloid leukemia by mutation-specific immunohistochemistry.
Byers R; Hornick JL; Tholouli E; Kutok J; Rodig SJ
Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):37-40. PubMed ID: 22172803
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Sells.
Badur MG; Muthusamy T; Parker SJ; Ma S; McBrayer SK; Cordes T; Magana JH; Guan KL; Metallo CM
Cell Rep; 2018 Oct; 25(4):1018-1026.e4. PubMed ID: 30355481
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
Upadhyay VA; Brunner AM; Fathi AT
Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
[TBL] [Abstract][Full Text] [Related]
11. Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia.
Fathi AT; Wander SA; Faramand R; Emadi A
Semin Hematol; 2015 Jul; 52(3):165-71. PubMed ID: 26111463
[TBL] [Abstract][Full Text] [Related]
12. Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML).
Steinhäuser S; Silva P; Lenk L; Beder T; Hartmann A; Hänzelmann S; Fransecky L; Neumann M; Bastian L; Lipinski S; Richter K; Bultmann M; Hübner E; Xia S; Röllig C; Vogiatzi F; Schewe DM; Yumiceba V; Schultz K; Spielmann M; Baldus CD
Leukemia; 2023 Jan; 37(1):134-142. PubMed ID: 36411356
[TBL] [Abstract][Full Text] [Related]
13. Integrated Metabolomics and Lipidomics Analyses Reveal Metabolic Reprogramming in Human Glioma with IDH1 Mutation.
Zhou L; Wang Z; Hu C; Zhang C; Kovatcheva-Datchary P; Yu D; Liu S; Ren F; Wang X; Li Y; Hou X; Piao H; Lu X; Zhang Y; Xu G
J Proteome Res; 2019 Mar; 18(3):960-969. PubMed ID: 30596429
[TBL] [Abstract][Full Text] [Related]
14. IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.
Ogawara Y; Katsumoto T; Aikawa Y; Shima Y; Kagiyama Y; Soga T; Matsunaga H; Seki T; Araki K; Kitabayashi I
Cancer Res; 2015 May; 75(10):2005-16. PubMed ID: 25795706
[TBL] [Abstract][Full Text] [Related]
15. SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.
DiNardo CD; Stein EM
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):769-772. PubMed ID: 30416011
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells.
Hujber Z; Petővári G; Szoboszlai N; Dankó T; Nagy N; Kriston C; Krencz I; Paku S; Ozohanics O; Drahos L; Jeney A; Sebestyén A
J Exp Clin Cancer Res; 2017 Jun; 36(1):74. PubMed ID: 28578659
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia.
Stuani L; Sabatier M; Saland E; Cognet G; Poupin N; Bosc C; Castelli FA; Gales L; Turtoi E; Montersino C; Farge T; Boet E; Broin N; Larrue C; Baran N; Cissé MY; Conti M; Loric S; Kaoma T; Hucteau A; Zavoriti A; Sahal A; Mouchel PL; Gotanègre M; Cassan C; Fernando L; Wang F; Hosseini M; Chu-Van E; Le Cam L; Carroll M; Selak MA; Vey N; Castellano R; Fenaille F; Turtoi A; Cazals G; Bories P; Gibon Y; Nicolay B; Ronseaux S; Marszalek JR; Takahashi K; DiNardo CD; Konopleva M; Pancaldi V; Collette Y; Bellvert F; Jourdan F; Linares LK; Récher C; Portais JC; Sarry JE
J Exp Med; 2021 May; 218(5):. PubMed ID: 33760042
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.
Wang JH; Chen WL; Li JM; Wu SF; Chen TL; Zhu YM; Zhang WN; Li Y; Qiu YP; Zhao AH; Mi JQ; Jin J; Wang YG; Ma QL; Huang H; Wu DP; Wang QR; Li Y; Yan XJ; Yan JS; Li JY; Wang S; Huang XJ; Wang BS; Jia W; Shen Y; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2013 Oct; 110(42):17017-22. PubMed ID: 24082129
[TBL] [Abstract][Full Text] [Related]
19. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Fathi AT; Sadrzadeh H; Borger DR; Ballen KK; Amrein PC; Attar EC; Foster J; Burke M; Lopez HU; Matulis CR; Edmonds KM; Iafrate AJ; Straley KS; Yen KE; Agresta S; Schenkein DP; Hill C; Emadi A; Neuberg DS; Stone RM; Chen YB
Blood; 2012 Nov; 120(23):4649-52. PubMed ID: 23074281
[TBL] [Abstract][Full Text] [Related]
20. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
